Alken Asset Management Ltd

Alken Asset Management Ltd is a London-based, FCA-authorised asset manager founded in 2005 by Nicolas Walewski. The firm is best known for high-conviction, fundamentally driven equity strategies, particularly in European and global developed markets. Its product line-up includes UCITS funds and segregated mandates that pursue concentrated stock-picking in long-only and, in some cases, long/short formats for institutional investors, wealth managers, and wholesale distributors. Alken’s flagship strategies typically hold a relatively limited number of positions versus broad benchmarks, reflecting the firm’s belief that outperformance is best achieved through deep research and meaningful active bets, rather than index-hugging. The team operates from London but invests globally, with U.S.-listed securities entering portfolios when they meet the same fundamental and valuation criteria applied to European holdings. Alken Asset Management Ltd files Form 13F with the U.S. Securities and Exchange Commission under CIK 0001629996. These filings cover the firm’s reportable long positions in U.S.-listed equities and certain equity-like instruments across mandates where it has investment discretion and where holdings exceed SEC thresholds. The 13F reports represent only the U.S.-listed portion of Alken’s strategies—often a subset of broader European or global equity portfolios—and exclude European listings, other non-U.S. securities, derivatives, cash, and any short positions. When the individual filings are assembled into a continuous 13F History, they allow a notional U.S. sleeve of Alken’s portfolios to be reconstructed at each quarter-end. That reconstruction is the empirical basis for analyzing the disclosed 13F Portfolio Composition and for deriving a 13F-based Historical Track Record for the firm’s U.S.-listed long book.

Alken’s investment philosophy is fundamentally oriented, valuation-aware, and benchmark-agnostic. The firm seeks to identify mispriced companies with attractive risk/reward profiles and is prepared to differ markedly from index sector and stock weights. Key elements of the process include: - Deep bottom-up research: Analysts and portfolio managers build detailed views on business models, competitive positioning, balance sheet quality, management, and long-term earnings power. They focus on understanding how a company makes money, how that may change, and how that is (or is not) reflected in the current price. - Valuation and quality discipline: Alken looks for companies that combine decent or improving fundamentals (cash-flow generation, returns on capital, balance sheet resilience) with valuations that offer a margin of safety. This typically leads to a GARP/value profile—owning growth where it is mispriced and avoiding expensive momentum. - High conviction, concentrated portfolios: Relative to broad benchmarks, Alken’s strategies usually hold a limited number of names, with position sizes meaningfully above index weights where conviction is highest. The firm accepts materially higher active share to pursue stock-specific alpha. The U.S.-listed component, as captured in 13F reports, reflects these principles applied to American and ADR-listed companies. While Alken is primarily associated with European equities, the 13F data often show selective positions in U.S. industrials, financials, consumer cyclicals and staples, and technology or healthcare names where the team believes the market misjudges long-term fundamentals or cyclical earnings power. Holding periods are typically multi-year, with turnover kept at low to moderate levels. Trading tends to be driven by thesis evolution—valuation converging toward intrinsic value, fundamental deterioration, or the emergence of superior opportunities—rather than by short-term factor or macro calls. The 13F footprint therefore tends to show a stable core of names over time, with incremental adjustments. For allocators using a Portfolio Simulator or Backtesting Service, Alken’s 13F History can be translated into a normalized portfolio of U.S.-listed holdings rebalanced on each filing date. That reconstruction provides a view on how the firm’s high-conviction, valuation-aware approach has expressed itself within the U.S. equity subset and how that subset has contributed to an overall Historical Track Record.

Alken Asset Management Ltd occupies a distinct space in the active equity universe as a London-based, high-conviction stock picker with a valuation- and quality-aware philosophy. Its U.S. advisory arm, reporting under CIK 0001629996, discloses a focused, fundamentally selected set of U.S.-listed positions that mirror the broader Orbis-style emphasis on mispriced businesses and benchmark-agnostic portfolio construction. When Alken’s 13F History is stitched into a coherent time series and examined within a Portfolio Simulator, an allocator can reconstruct a normalized portfolio representing the firm’s reportable long U.S. equity exposures. Structurally, the time evolution of the 13F Portfolio Composition highlights how Alken has shifted capital among sectors, themes, and individual names as valuation spreads, sector leadership, and company fundamentals have changed. Outcome-wise, the inferred Historical Track Record, together with indicative efficiency diagnostics such as a reconstructed Sharpe Ratio and observed Max Drawdown Depth, provides a data-grounded view of how the U.S.-listed sleeve has navigated equity bull and bear markets, style rotations, and episodes of heightened dispersion in valuations. Because Form 13F illuminates only the U.S.-listed portion of a broader European and global equity platform, these analytics should be treated as a focused, long-only lens on one facet of Alken’s process, not as a complete portrait of all mandates. The key open question for allocators and oversight committees is how the regime sensitivity implied by this reconstructed U.S. sleeve—its reliance on valuation mean reversion, tolerance for concentration, and exposure to cyclical and out-of-favor segments—aligns with the role they envisage for a high-conviction, fundamental manager within a diversified multi-manager or multi-asset allocation.

The risk profile of Alken Asset Management Ltd, viewed through its 13F-reported U.S. positions, reflects the hallmarks of concentrated, benchmark-agnostic, fundamental stock picking. Key structural risk characteristics include: - Active risk and tracking error: Concentrated positions and contrarian valuation stances generate meaningful tracking error versus cap-weighted indices. In environments dominated by narrow growth or momentum leadership, portfolios may diverge significantly from index returns, both positively and negatively. - Sector and cyclical exposure: Although there is no fixed sector bias, Alken’s value-aware approach can lead it to overweight more cyclical or out-of-favor areas (for example, selected financials, industrials, or consumer cyclicals) when they screen attractively. This can increase sensitivity to economic cycles and factor rotations between growth and value, defensives and cyclicals. - Single-name and idiosyncratic risk: With a relatively small number of holdings and meaningful position sizes, portfolio outcomes are influenced by company-specific events—earnings surprises, regulatory changes, competitive shifts, or management actions. The firm manages this risk through diversification across themes and rigorous research, but idiosyncratic volatility remains a key component of the risk budget. By linking each 13F-reported security to its historical price series and reconstructing a time series of notional portfolio values for the U.S.-listed sleeve, allocators can estimate realized volatility and drawdown behavior of the long-only U.S. component. A central downside diagnostic in this analysis is historical Max Drawdown Depth, which measures the steepest peak-to-trough decline experienced by the reconstructed portfolio over the observation window and summarizes how the combination of equity market beta, value tilts, and concentration has translated into capital impairment during adverse regimes. From the same reconstructed capital path, risk-adjusted outcome metrics such as an indicative Sharpe Ratio can be derived, placing the variability of the U.S. sleeve in the context of its long-run compounding profile. Interpreted alongside the evolving 13F Portfolio Composition—including sector weights, concentration in top positions, and the breadth of the issuer set—these diagnostics yield a practical Volatility Profile for the portion of Alken’s activity that is transparent via Form 13F and can be interrogated using Performance Backtests Online. It is important to remember that this 13F-based view is partial. European and other non-U.S. holdings, any use of derivatives or shorts in long/short strategies, and cash allocations are not captured in the U.S. equity filings but are important contributors to the total risk and return profile experienced by Alken’s investors.